



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, DC 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
097073.138	05/05/98	KAWAKAMI	Y 2026-4124US3

WILLIAM S FEILER
MORGAN & FINNEGAN
345 PARK AVENUE
NEW YORK NY 10154

HM21/0701

EXAMINER

HUFF, S

ART UNIT

1642

PAPER NUMBER

DATE MAILED:

07/01/98

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.

09/073,138

Applicant(s)

Kawakami et al

Examiner

Sheela J. Huff

Group Art Unit

1642



☐ Responsive to communication(s) filed on _____

☐ This action is **FINAL**.

☐ Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire zero month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

☒ Claim(s) 1-38 is/are pending in the application.

Of the above, claim(s) _____ is/are withdrawn from consideration.

☐ Claim(s) _____ is/are allowed.

☐ Claim(s) _____ is/are rejected.

☐ Claim(s) _____ is/are objected to.

☒ Claims 1-38 are subject to restriction or election requirement.

Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on _____ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on _____ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been
☐ received.

☐ received in Application No. (Series Code/Serial Number) _____

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

☐ Notice of References Cited, PTO-892

☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). _____

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Serial Number: ~~08~~ 09/073138
Art Unit: 1642

-2-

Part III DETAILED ACTION

Election/Restriction

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

Group I. Claims 1-14, drawn to peptides of MART-1, classified in Class 530, subclass 328 and 350+.

Group II. Claims 15-26, ^{and 29-31} drawn to peptides of gp100, classified in Class 530, subclass 328.

Group III. Claims 32-35, drawn to nucleic acid sequences and vectors, classified in Class 536, subclass 23.1+.

Group IV. Claims 36-38, drawn to antibodies, classified in Class 530, subclass 387.7.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I-IV are disclosed as different combinations which are not connected in design, operation or effect. These combinations are independent if it can be shown that (1) they are not disclosed as capable of use together, (2) they have different modes of operation, (3) they have different functions, or (4) they have different effects. (MPEP 806.04, MPEP 808.01). In the instant case the combinations are unrelated in chemical composition and structure, in physicochemical properties and in function.

Serial Number: ⁹08/093138

-3-

Art Unit: 16612

Specifically, the nucleic acid sequence of Invention III can be used to synthesize a protein whereas the antibody of Invention IV or the proteins or peptides of Inventions I and II cannot. The antibody of Invention IV can be used to produce an immunogen for making anti-idiotypic antibodies whereas the nucleic acid sequence of Invention III cannot. The proteins and peptides of Invention I and II can be also be used as an immunogen where as the nucleic acid sequence of Invention III cannot. The protein and peptides of Invention I and II are different amino acid sequences and therefore are chemically and structurally different. Similarly, the antibody of Invention IV and the proteins or Inventions I or II are also chemically and structurally different products. Thus, the products of Inventions I-IV are separate and patentably distinct from each other.

3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

4. Because these inventions are distinct for the reasons given above and the search required for Invention I is not required for Inventions II-IV, the search required for Invention II is not required for Inventions I and III-IV, the search required for Invention III is not required for Inventions I-II and IV, the search required for Invention IV is not required for Inventions

Serial Number: 09/073138
Art Unit: 1642

-4-

I-III restriction for examination purposes as indicated is proper.

Election of Species

5. This application contains claims directed to the following patentably distinct species of the claimed invention:

- a. If applicant elects either Group I or Group II, then applicant should elect either MART-1 or gp100 of claims 27-~~28~~. For example, if applicant elects Group I, then claims 27-~~28~~ (referring to MART-1) will be examined with Group I.
- b. If applicant elects Group III, then applicant should elect either MART-1 or gp100.
- c. If applicant elects Group VI, then applicant should elect either MART-1 or gp100.

As explained above, MART-1 and gp100 are distinct proteins encoded by distinct nucleic acid sequences and thus are chemically and structurally unrelated.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, either claims 1-14 or claim 15-26 is generic.

Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An

Serial Number: 09/073138

-5-

Art Unit: 1042

argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

6. No attempt was made to call the attorney of record to request an oral election to the above restriction requirement because of the complexity of the restriction.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

Serial Number: 09/073138

-6-

Art Unit: 1642

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheela J. Huff whose telephone number is (703) 305-7866. The examiner can normally be reached on Monday-Thursday from 6:30am to 3:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marian Knode, can be reached on (703) 308-4311. The FAX phone number for this Group is (703)308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Sheela J. Huff

6/29/98

Sheela J. Huff

SHEELA HUFF
PRIMARY EXAMINER